Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 149, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2022.112801
Keywords
Long noncoding RNA; MNX1-AS1; Cancer; Oncogenic; Biomarker
Funding
- Provincial Key Laboratory of Medical Physics and Technology Safety and Security Open Fund [LMPT201908, 2020LCZD07]
- Study of environ-mental pathogenic factors and mechanisms of metabolic diseases Research [2021lcxk033, 2019GQFY07]
Ask authors/readers for more resources
This article highlights the crucial role of long non-coding RNAs (lncRNAs) in cancer pathogenesis and specifically focuses on the potential functions of MNX1-AS1 in various cancer types and its potential as a therapeutic target.
To date, recent studies have shown that long non-coding RNAs (lncRNAs) are key players in gene regulation processes involved in cancer pathogenesis. In general, Motor neuron and pancreas homeobox 1-antisense RNA1 (MNX1-AS1) is highly expressed in all cancers as reported so far and exerts oncogenic effects through different mechanisms. In this review, we comprehensively summarize the detailed mechanisms of potential functions of MNX1-AS1 in different cancer types as well as the latest knowledge highlighting the potential of MNX1-AS1 as a therapeutic target for cancer. Aberrant expression of MNX1-AS1 closely correlates with clinicopathological parameters. such as lymphatic metastasis, tumor size, tumor stage, OS and DFS. Thus, MNX1-AS1 can be used as a diagnostic and prognostic biomarker or even a therapeutic prognostic target. This article reviews its function, molecular mechanism and clinical prognosis in various malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
